Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 295 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Constrictive Bronchiolitis Clear all
Completed Phase 1Phase 2 Interventional Results available

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

NCT01111526
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Panobinostat (LBH589)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 21, 2026, 7:45 PM EDT
Recruiting Phase 2 Interventional

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT06660355
View directory record Official record
Conditions
Chronic Graft-versus-host Disease (cGVHD)
Interventions
Ruxolitinib, Prednisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Miami, Florida • Tampa, Florida • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 21, 2026, 7:45 PM EDT
Recruiting Phase 2 Interventional

Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

NCT06419439
View directory record Official record
Conditions
Chronic Low Back Pain, Depression
Interventions
Ketamine hydrochloride, Minimally Enhanced Usual Care, Brief narrative intervention
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients

NCT00660530
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Disease
Interventions
Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 2 Interventional

Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain

NCT00838799
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
RGH-896, pregabalin, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Mesa, Arizona • Tempe, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Jul 21, 2026, 7:45 PM EDT
Recruiting Phase 2 Interventional

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue.

NCT05584124
View directory record Official record
Conditions
Stroke, Stroke, Chronic, Fatigue
Interventions
High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
34 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

NCT01919697
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
2,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
211
States / cities
Birmingham, Alabama • Dothan, Alabama • Gulf Shores, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Jul 21, 2026, 7:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

NCT04200365
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Itacitinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Denver, Colorado • Nashville, Tennessee • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Jul 21, 2026, 7:45 PM EDT
Not listed Phase 2 Interventional

Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

NCT01158105
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Bortezomib
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

NCT03483675
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Immunosuppressive Therapy, Survey Administration
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab for Prevention of Chronic GVHD

NCT00379587
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Rituximab, 375 mg/m2 RRituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Jul 21, 2026, 7:45 PM EDT
Recruiting Phase 2 Interventional

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

NCT07354074
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Interventions
Asciminib single agent
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

NCT02195869
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Duarte, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jul 21, 2026, 7:45 PM EDT
Completed No phase listed Observational

Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.

NCT01174277
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Graft Versus Host Disease
Interventions
Collection of blood sample
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
7 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Jul 21, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain

NCT07214844
View directory record Official record
Conditions
Low Back Pain, Chronic
Interventions
Iovera Medial Branch Cryoneurolysis, Radiofrequency ablation (RFA)
Device · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01578707
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
ofatumumab, ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Jul 21, 2026, 7:45 PM EDT
Terminated Phase 3 Interventional

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Jul 21, 2026, 7:45 PM EDT
Recruiting Phase 3 Interventional

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
32
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

NCT02036970
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
Interventions
Bardoxolone methyl, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 21, 2026, 7:45 PM EDT
Terminated Not applicable Interventional Results available

Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE

NCT01775735
View directory record Official record
Conditions
Migraine Disorders
Interventions
Occipital nerve stimulator
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Valencia, California • Chicago, Illinois • Shreveport, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Wearable Robotic Functional Assistance for Stroke Rehabilitation

NCT00396708
View directory record Official record
Conditions
CVA (Cerebrovascular Accident)
Interventions
myomo e100 neurorobotic elbow brace
Device
Lead sponsor
Myomo
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 1 Interventional

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

NCT05121142
View directory record Official record
Conditions
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jul 21, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

NCT02649218
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 21, 2026, 7:45 PM EDT